Brian A. Bergmark MDInvestigator, TIMI Study Group and Interventional Cardiologist, Complex Coronary/CTO Program, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massacusetts
Brian Bergmark, MD is an Interventional Cardiologist in the Chronic Total Occlusion/Complex Coronary Intervention Program at the Brigham and Women's Hospital, Harvard Medical School and is an Investigator at the TIMI Study Group. He is an Associate Program Director for the combined Mass General Brigham CTO/Complex Coronary Intervention fellowship. He received his BA from Stanford University and his MD from Harvard Medical School.
Dr. Bergmark reports the following:
Research grants (through the Brigham and Women’s Hospital): Pfizer, Ionis, Quark, AstraZeneca/MedImmune, Amgen
Consulting/personal fees: Philips, Abbott Vascular, CSI, Abiomed, Servier, Janssen, Quark, Daiichi Sankyo
Dr. Bergmark is a member of the TIMI Study Group, which has received grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia, Ionis, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Roche, Siemens Healthcare Diagnostics, Inc., The Medicines Company, and Zora Biosciences.